Skip to main content
. 2015 Aug 31;182(2):162–172. doi: 10.1111/cei.12689

Table 1.

Biometric data of all volunteers included in this study.

Total number of relapse Duration of IFN-β1b treatment in years
n m/f Age in years Duration of MS in years Before treatment Under treatment
Healthy controls 20 3/17 34·1 ± 11·3
MS patients without DMT 18 6/12 35·2 ± 11·3 6·5 ± 9·4 2·2 ± 2·3
IFN-β1b-treated MS patients 10 3/7 41·4 ± 9·5 8·9 ± 8·4 3·1 ± 3·0 1·5 ± 1·4 4·5 ± 5·2

m = male; f = female. Mean values ± SD are shown.